Laakso M
Department of Medicine, University of Kuopio, Kuopio, Finland.
J Intern Med. 2001 Mar;249(3):225-35. doi: 10.1046/j.1365-2796.2001.00789.x.
Type 2 diabetes increases the risk of cardiovascular disease (CVD) two- to fourfold compared with the risk in non-diabetic subjects. Although type 2 diabetes is associated with a clustering of risk factors (small, dense low-density lipoprotein [LDL] particles, low high-density lipoprotein [HDL] cholesterol, high triglycerides, elevated blood pressure, obesity, central obesity, hyperinsulinaemia, hyperglycaemia, etc.), the cause for an excess risk of CVD remains unknown. Recent drug treatment trials have indicated that the lowering of total and LDL cholesterol and blood pressure is similarly beneficial in diabetic and non-diabetic subjects. The treatment of hyperglycaemia reduces micro- and macrovascular complications in type 2 diabetic patients. Beta-blocking agents, angiotensin-converting enzyme inhibitors, aspirin, and thrombolytic therapy are also effective in the treatment of CVD amongst diabetic patients.
与非糖尿病患者相比,2型糖尿病使心血管疾病(CVD)的风险增加两到四倍。尽管2型糖尿病与多种危险因素聚集相关(小而致密的低密度脂蛋白[LDL]颗粒、低高密度脂蛋白[HDL]胆固醇、高甘油三酯、血压升高、肥胖、中心性肥胖、高胰岛素血症、高血糖等),但CVD风险过高的原因仍不明。近期的药物治疗试验表明,降低总胆固醇和LDL胆固醇以及血压对糖尿病和非糖尿病患者同样有益。高血糖的治疗可减少2型糖尿病患者的微血管和大血管并发症。β受体阻滞剂、血管紧张素转换酶抑制剂、阿司匹林和溶栓治疗对糖尿病患者的CVD治疗也有效。